Neuphoria Therapeutics (NEUP) EBIT (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported EBIT for 4 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, EBIT fell 110.12% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$16.8 million, a 2071.23% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 93.69% from the prior year.
• EBIT was -$1.2 million for Q1 2026 at Neuphoria Therapeutics, up from -$4.1 million in the prior quarter.
• Over five years, EBIT peaked at $12.0 million in Q1 2025 and troughed at -$5.8 million in Q2 2025.
• A 4-year average of -$2.7 million and a median of -$4.1 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 600.29% in 2025 and tumbled 110.12% in 2026, its largest moves.
• Over 4 years, EBIT stood at -$4.6 million in 2023, then grew by 18.66% to -$3.7 million in 2024, then slipped by 9.65% to -$4.1 million in 2025, then soared by 70.16% to -$1.2 million in 2026.
• The last three EBIT figures came in at -$1.2 million (Q1 2026), -$4.1 million (Q4 2025), and -$5.7 million (Q3 2025), per Business Quant data.